<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Human leukocyte antigen-G (HLA-G) molecule exerts multiple immunoregulatory functions that have been suggested to contribute to the immune evasion of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> cells </plain></SENT>
<SENT sid="1" pm="."><plain>Studies on HLA-G expression in malignant haematopoietic diseases are controversial, and the functions of HLA-G on this context are limited </plain></SENT>
<SENT sid="2" pm="."><plain>In the current study, HLA-G expression was analysed in different types of patients: de novo <z:hpo ids='HP_0011009'>acute</z:hpo> <z:mpath ids='MPATH_342'>myeloid leukaemia</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, n = 54), B cell <z:hpo ids='HP_0011009'>acute</z:hpo> lymphoblastic <z:mpath ids='MPATH_336'>leukaemia</z:mpath> (<z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e>, n= 13), <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:mpath ids='MPATH_342'>myeloid leukaemia</z:mpath> (<z:mp ids='MP_0005481'>CML</z:mp>, n= 9) and <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, n= 11) </plain></SENT>
<SENT sid="3" pm="."><plain>HLA-G expression was observed in 18.5% cases of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, 22.2% in <z:mp ids='MP_0005481'>CML</z:mp> and 18.2% in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, but not in <z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e> patients </plain></SENT>
<SENT sid="4" pm="."><plain>In <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, HLA-G-positive patients had a significant higher bone marrow leukaemic blast cell percentage when compared with that of HLA-G-negative patients (P &lt; 0.01) </plain></SENT>
<SENT sid="5" pm="."><plain>Total T-cell percentage was dramatically decreased in HLA-G-positive patients (P &lt; 0.05) </plain></SENT>
<SENT sid="6" pm="."><plain>Cytogenetic karyotyping results showed that <z:hpo ids='HP_0000001'>all</z:hpo> HLA-G-positive <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> patients (n= 5) were cytogenetically abnormal, which was markedly different from that of HLA-G-negative patients (P &lt; 0.01) </plain></SENT>
<SENT sid="7" pm="."><plain>Ex vivo cytotoxicity analysis revealed that HLA-G expression in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> leukaemic cells could directly inhibit NK cell cytolysis (P &lt; 0.01) </plain></SENT>
<SENT sid="8" pm="."><plain>These findings indicated that HLA-G expression in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> is of unfavourable clinical implications, and that HLA-G could be a potential target for therapy </plain></SENT>
</text></document>